Chief financial officer

SeaSpine® Announces New Senior Leadership Team Appointments

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, U.S. Securities and Exchange Commission, Neurosurgery, Senior, Culture, Health, NASDAQ, GLOBE, Company, Navigation, Software, Patient, Security (finance), SPNE, Thermo Fisher Scientific, Organization, Acquisition, Chief financial officer, MIS, Marketing, Spine, Human resources, Surgeon, National Center for Spinal Disorders, CEO, News, Growth, Spinal fusion, Risk, Management, Risk management

In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources.

Key Points: 
  • In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources.
  • With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team.
  • He has been an influential leader in enabling and financing SeaSpines growth and has assumed increasing operational responsibilities during his tenure.
  • In collaboration with senior leadership, Hollis will continue to build a culture that attracts, retains and develops the talent needed to provide the best in spine patient care.

ZT Corporate Unveils New Office Space in Midtown Manhattan

Retrieved on: 
Friday, April 8, 2022
Professional Services, Health, Other Construction & Property, Other Health, Finance, Construction & Property, Investment, Health, Growth, Multimedia, ZT, Chief financial officer, CEO, Senior, Neighbor, Chief executive officer, Private equity, VP, AVP, Corporation, Interior design, Film, Financial services

ZT Corporate , a private equity firm that specializes in healthcare and automotive investments, unveiled its new office in New York Citys desirable Plaza District.

Key Points: 
  • ZT Corporate , a private equity firm that specializes in healthcare and automotive investments, unveiled its new office in New York Citys desirable Plaza District.
  • To mark the occasion, a grand opening celebration was recently held with ZT Corporate team members and stakeholders.
  • Established in 1997, ZT Corporate is a private equity firm with an active portfolio in healthcare services and automotive dealerships.
  • ZT Corporates active healthcare portfolio operates under Altus Healthcare and Neighbors, with automotive dealerships branded under the ZT Motors umbrella.

UN Global Compact launches CFO Coalition for the SDGs to drive more private sector investment towards sustainable development

Retrieved on: 
Tuesday, March 29, 2022
Sustainable Development Goals, UN, Investment, Enel, Goal, CFO, Research, Climate, Environment, PIMCO, United Nations Global Compact, SDG, Integration, Ten Principles for the Establishment of a Monolithic Ideological System, Lead, Sustainable development, Senior advisor, COVID-19, Global Compact, Signature, GLOBE, CFOS, Policy, Movement, Coalition, Chief financial officer, Transport, Financial services, Renewable energy, Consultant, Management

It is made up of a CFO Leadership Group which guides the work of the CFO Coalition for the SDGs and a number of Signatories who commit to the CFO Principles on Integrated SDG Investments and Finance .

Key Points: 
  • It is made up of a CFO Leadership Group which guides the work of the CFO Coalition for the SDGs and a number of Signatories who commit to the CFO Principles on Integrated SDG Investments and Finance .
  • Foster a community of 1,000 CFO Signatories to the CFO Principles on Integrated SDG Investments and Finance by 2024.
  • Jerome Lavigne-Delville, Senior Advisor, Sustainable Finance and Co-Lead of the CFO Coalition for the SDGs at the UN Global Compact said:
    CFOs have a leading role to play in setting and aligning sustainability and financial targets.
  • The CFO Coalition for the SDGs is at the vanguard of a new movement which recognises CFOs as the architects of long-term value creation.

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

Retrieved on: 
Tuesday, March 22, 2022
Company, Chief business officer, LinkedIn, Organization, Board, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, State university system, Advaxis, Urologic disease, Vonoprazan, Chief financial officer, Drugs for acid-related disorders, Buffalo, Senior, Industry, Director, Twitter, MS, Nasdaq, MBA, GLOBE, Degenerative disease, Audit committee, Pharmaceutical industry, Management

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.

Key Points: 
  • FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer.
  • Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (Nasdaq: URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease.
  • Molly brings to Phathom deep financialacumenand significant industry experience across mid-size and large-scalecommercialorganizations, and we are excited to have her join our executive leadership team, said Terrie Curran, President and Chief Executive Officer of Phathom.
  • She was previously the Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Ms. Henderson holds an MBA and MS in Accounting from the State University of New York at Buffalo.

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors

Retrieved on: 
Tuesday, March 15, 2022
Therapy, Chief financial officer, Roche, Humboldt University of Berlin, University, GLOBE, Doctor of Philosophy, Board of directors, Partnership, Director, Trust, CFO, Harvard Business School, Biogen, NASDAQ, BBB, Economics, Biomarker, Board, Leadership, Growth, Traffic barrier, Merrill (company), Neurodegeneration, SAN, Wharton School of the University of Pennsylvania, Wendell Pritchett, Sanofi, Management, Takeda, Genentech

Denalis Chief Operating Officer Alexander Schuth, M.D., will add the Chief Financial Officer role to his current responsibilities, becoming Denalis Chief Operating and Financial Officer.

Key Points: 
  • Denalis Chief Operating Officer Alexander Schuth, M.D., will add the Chief Financial Officer role to his current responsibilities, becoming Denalis Chief Operating and Financial Officer.
  • We are excited to see Alexs role expand at Denali as he takes on the combined position of Chief Operating and Financial Officer.
  • With this transition from the CFO role to the Board of Directors, I can continue to contribute to Denali's business and financial strategy, while achieving my personal desire to move back home to Europe, said Steve Krognes, Denalis Chief Financial Officer.
  • Alexander Schuth is a co-founder of Denali Therapeutics and has served as the Chief Operating Officer and Secretary since 2015.

Good Times Restaurants Inc. Welcomes Matthew Karnes as Senior Vice President of Finance and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 8, 2022
Professional Services, Retail, Communications, Finance, Food, Beverage, Public Relations, Investor Relations, FP, Employment, University, Weather, Organization, Annual report, Music, Nasdaq, Culture, Chief financial officer, Pachacútec City Special Project, Option, Restaurant, Denver International Airport, Multimedia, SEC, Company, Good Times, COVID-19, Senior, Food, Good Times Burgers & Frozen Custard, Bad, Risk, Good, Coronavirus, Suretrack Contracts Services, Opportunity, Achievement, Fast food, Management, Security (finance), Finance

Good Times Restaurants Inc. (GTIM) (the Company), operator of Bad Daddys Burger Bar and Good Times Burgers & Frozen Custard, today announced that Matthew Karnes has been named Senior Vice President of Finance.

Key Points: 
  • Good Times Restaurants Inc. (GTIM) (the Company), operator of Bad Daddys Burger Bar and Good Times Burgers & Frozen Custard, today announced that Matthew Karnes has been named Senior Vice President of Finance.
  • From November 2015 to August 2018, Matthew was the Finance Director for FP&A and Contract Services at Denver International Airport.
  • "I am delighted to welcome Matthew to the Good Times Restaurants team," said Ryan Zink, President and Chief Executive Officer.
  • About Good Times Restaurants Inc.:
    Good Times Restaurants Inc. (GTIM) owns, operates, franchises and licenses 42 Bad Daddys Burger Bar restaurants through its wholly owned subsidiaries.

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

Retrieved on: 
Tuesday, February 22, 2022
Lung, BTG, Commercial Operating System (COS), Neoplasm, Growth, Initial public offering, The Toxic Avenger (film), Company, Sale, Business, FirstMark Capital, Ovation Pharmaceuticals, Cancer, Rice University, Corporate development, Multimedia, The Company, Biotechnology, View, Trinity College, Business development, Cowen, Patient, Technology, Chief financial officer, Immunotherapy, IPO, Pequot Capital Management, Ovarian cancer, Pharmaceutical industry, Management, Avenger, Collegium (ancient Rome)

NATICK, Mass., Feb. 22, 2022 /PRNewswire/ -- Avenge Bio, Inc., ("Avenge" or the "Company") a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the appointment of Douglas Carlson as its Chief Operating and Financial Officer.

Key Points: 
  • NATICK, Mass., Feb. 22, 2022 /PRNewswire/ -- Avenge Bio, Inc., ("Avenge" or the "Company") a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the appointment of Douglas Carlson as its Chief Operating and Financial Officer.
  • "Avenge Bio is in a period of significant growth following our recent financing and Doug will play a vital role in implementing and executing our long-term strategy," said Michael Heffernan, Chief Executive Officer of Avenge.
  • "I am thrilled to be joining the Avenge team at such an important time for the Company," said Mr. Carlson.
  • Most recently he was the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of Ikena Oncology, Inc. At Ikena, he raised over $260M in private and public capital, led the company's Initial Public Offering (IPO) in March 2021, and built a robust infrastructure to hire and integrate over 50 new employees.

Nuo Therapeutics Responds to Mini-Tender Offer

Retrieved on: 
Friday, February 4, 2022
GLOBE, U.S. Securities and Exchange Commission, OTC Markets Group, Disclosure, Company, Schedule, Compliance, SEC, LP, Securities Exchange Act of 1934, Chief financial officer, Nature, Communication, Security (finance), Audit, Nuo

HOUSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (Nuo or the Company) announced that it is aware of an unsolicited mini-tender offer by Alternative Liquidity Index, LP to purchase up to 1,820,000 shares of Nuo common stock, approximately 4.9% of the outstanding shares, at $0.01 per share.

Key Points: 
  • HOUSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (Nuo or the Company) announced that it is aware of an unsolicited mini-tender offer by Alternative Liquidity Index, LP to purchase up to 1,820,000 shares of Nuo common stock, approximately 4.9% of the outstanding shares, at $0.01 per share.
  • Nuo is not associated with Alternative Liquidity Index, LP or its mini-tender offer.
  • Nuo expresses no opinion and is remaining neutral toward the mini-tender offer.
  • This communication does not constitute an offer to buy or solicitation of an offer to sell any securities.

Chimerix to Present at B. Riley Virtual Oncology Conference

Retrieved on: 
Thursday, January 20, 2022
Patient, Conference, Investor relations, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, GLOBE, ONC201, Chief financial officer, Acute myeloid leukemia, Smallpox, Company, Food, Sodium, Pharmaceutical industry

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

Key Points: 
  • An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
  • Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT).

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

Retrieved on: 
Monday, January 3, 2022
Acute myeloid leukemia, Smallpox, GLOBE, Investor relations, Company, ONC201, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Conference, Sodium, Patient, Chief financial officer, Pharmaceutical industry

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

Key Points: 
  • An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
  • Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT).